Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a first-in-human study titled ‘First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies.’ This study aims to assess the safety and effectiveness of ABBV-101 in treating various subtypes of non-Hodgkin’s lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
The intervention being tested is ABBV-101, an investigational oral drug designed to treat NHL by degrading BTK, a protein involved in cancer cell survival. The study will determine the maximum tolerated dose and evaluate changes in disease activity.
The study is interventional, with a randomized and sequential design. It is unmasked, meaning both researchers and participants know the treatment being administered. The primary goal is to treat NHL effectively.
The study began on June 9, 2023, and is expected to last approximately 88 months. The last update was submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This study could significantly impact AbbVie’s stock performance by potentially introducing a new treatment for NHL, enhancing its competitive position in the oncology market. Investors should watch for updates as the study progresses, considering the broader industry context.
The study is ongoing, with further details available on the ClinicalTrials portal.